Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk

por Goldenberg, Naila, Glueck, Charles
Publicado 2009

Severe Vitamin D Deficiency, Myopathy, and Rhabdomyolysis

por Glueck, Charles J, Conrad, Brandon
Publicado 2013

Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events

por Glueck, Charles J., Goldenberg, Naila, Wang, Ping
Publicado 2018

Statin Intolerance and Vitamin D Supplementation

por Khayznikov, Maksim, Kumar, Ashwin, Wang, Ping, Glueck, Charles J.
Publicado 2015

Long Term Anticoagulation (4–16 Years) Stops Progression of Idiopathic Hip Osteonecrosis Associated with Familial Thrombophilia

por Glueck, Charles J., Freiberg, Richard A., Wissman, Robert, Wang, Ping
Publicado 2015

Risk factors for cardiovascular disease and type 2 diabetes retained from childhood to adulthood predict adult outcomes: the Princeton LRC Follow-up Study

por Morrison, John A, Glueck, Charles J, Woo, Jessica G, Wang, Ping
Publicado 2012

Thrombophilia and retinal vascular occlusion

por Glueck, Charles J, Hutchins, Robert K, Jurantee, Joel, Khan, Zia, Wang, Ping
Publicado 2012

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes

por Kurtz, Will S, Glueck, Charles J, Hutchins, Robert K, Sisk, Robert A, Wang, Ping
Publicado 2016

Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy...

por Glueck, Charles J, Khan, Naseer, Riaz, Muhammad, Padda, Jagjit, Khan, Zia, Wang, Ping
Publicado 2012

Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation

por Khayznikov, Maksim, Hemachrandra, Kallish, Pandit, Ramesh, Kumar, Ashwin, Wang, Ping, Glueck, Charles J
Publicado 2015

Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Yea...

por Glueck, Charles J., Lee, Kevin, Prince, Marloe, Jetty, Vybhav, Shah, Parth, Wang, Ping
Publicado 2016

Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity

por Schockman, Samantha, Glueck, Charles J, Hutchins, Robert K, Patel, Jaykumar, Shah, Parth, Wang, Ping
Publicado 2015

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

por Choi, Joshua, Khan, Amir M, Jarmin, Michael, Goldenberg, Naila, Glueck, Charles J, Wang, Ping
Publicado 2017

High-Sensitivity C Reactive Protein: Associations with Cardiovascular Risk Factors and Tracking in Female Adolescents and Young Adults

por Morrison, John A., Glueck, Charles J., Daniels, Stephen R., Wang, Ping, Stroop, Davis M., Horn, Paul S.
Publicado 2011

Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance

por Jetty, Vybhav, Glueck, Charles J, Wang, Ping, Shah, Parth, Prince, Marloe, Lee, Kevin, Goldenberg, Michael, Kumar, Ashwin
Publicado 2016

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

por Shah, Parth, Glueck, Charles J., Jetty, Vybhav, Goldenberg, Naila, Rothschild, Matan, Riaz, Rashid, Duhon, Gregory, Wang, Ping
Publicado 2016

Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes

por Dixon, Stephan G, Bruce, Carl T, Glueck, Charles J, Sisk, Robert A, Hutchins, Robert K, Jetty, Vybhav, Wang, Ping
Publicado 2016

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated ch...

por Glueck, Charles J., Shah, Parth, Goldenberg, Naila, Prince, Marloe, Lee, Kevin, Jetty, Vybhav, Kumar, Ashwin, Goldenberg, Michael, Wang, Ping
Publicado 2016

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated c...

por Shah, Parth, Glueck, Charles J., Goldenberg, Naila, Min, Sarah, Mahida, Chris, Schlam, Ilana, Rothschild, Matan, Huda, Ali, Wang, Ping
Publicado 2017

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite...

por Jetty, Vybhav, Glueck, Charles J, Lee, Kevin, Goldenberg, Naila, Prince, Marloe, Kumar, Ashwin, Goldenberg, Michael, Anand, Ishan, Wang, Ping
Publicado 2017